iota Biosciences Receives FDA Approval for Pioneering Device
iota Biosciences, Inc., a subsidiary of Astellas Pharma Inc., has recently garnered approval from the U.S. Food and Drug Administration (FDA) to proceed with a significant investigational study. The study will focus on evaluating a novel implantable device designed to assist individuals suffering from underactive bladder (UAB) by delivering targeted electrical stimulation to the bladder wall.
The Study's Structure and Purpose
The FDA's approval encompasses a carefully structured Early Feasibility Study (EFS) aimed at ensuring the device's safety and functionality. In the initial phase, three participants will be enrolled, selecting individuals of diverse gender representation. Based on the successful safety outcomes observed after this first stage, the study plans to expand, ultimately including a total of ten participants.
Understanding Underactive Bladder
Underactive bladder is a complex condition that manifests through a variety of symptoms, including a slow urinary stream, difficulty starting urination, and the sensation of incomplete bladder emptying. This condition significantly affects circa 28% of men over 50 and 45% of older women globally, with alarming prevalence in men aged 70 and older—up to 48% are impacted. Recognizing the urgent need for effective treatment options is essential, as existing solutions often fall short.
Comments from the Leadership Team
Dr. Michel Maharbiz, the CEO of iota Biosciences, expressed his enthusiasm about this advancement, stating, "The current treatment options for underactive bladder are limited, often compelling patients to resort to clean intermittent catheterization. This process can be cumbersome and may lead to various complications. Our commitment to innovation and patient care drove the rapid progress from concept to IDE approval in under four years. We're excited about the potential of this device to bring relief to those in need."
Adam Pearson, Chief Strategy Officer of Astellas, also shared his insights: "The initiation of this early feasibility study reflects our ongoing dedication to expanding treatment options beyond conventional pharmaceuticals. We aim to bring new science and technology to bear on healthcare challenges. The progress of this study could significantly enhance the lives of individuals affected by underactive bladder."
iota's Commitment to Bioelectronic Solutions
Astellas's acquisition of iota Biosciences in 2020 marked a critical step in the exploration of bioelectronic technologies aiming to meet the needs of patients with challenging health conditions.
About Astellas Pharma Inc.
Astellas is a leader in the pharmaceutical industry, operating across more than 70 countries globally. The company's Focus Area Approach seeks to continuously discover and develop drugs that address pressing medical needs through innovative biological and technological methods.
About iota Biosciences
Founded in 2017, iota is dedicated to pioneering advancements in bioelectronic medicine. The organization is on a mission to create advanced diagnostic and therapeutic devices that offer safe and effective solutions. By harnessing proprietary wireless technologies, iota aims to transform the landscape of disease management, empowering healthcare providers and improving the lives of patients.
Frequently Asked Questions
What is the purpose of the Early Feasibility Study?
The EFS aims to evaluate the safety and feasibility of an implantable device for treating underactive bladder through electrical stimulation.
Who are the participants in the study?
The initial phase will involve three participants, selected to ensure a representative sample, with potential expansion to ten participants based on safety results.
What are the common symptoms of underactive bladder?
Symptoms include a slow urinary stream, difficulty initiating urination, maintaining the stream, and feeling of incomplete emptying.
Who leads iota Biosciences, and what is their vision?
Dr. Michel Maharbiz leads iota Biosciences, focusing on innovative solutions that address the limitations of current treatment methods for bladder disorders.
What areas does Astellas Pharma serve?
Astellas Pharma operates in over 70 countries, focusing on developing solutions to meet unmet medical needs through innovative pharmaceuticals and advanced healthcare technologies.
